Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer-based COVID-19 vaccine ZF2001 in chronic hepatitis B patients.

ABSTRACT:

Background and aims

Although COVID-19 vaccination is recommended for the patients with chronic liver disease, the clinical outcomes of COVID-19 vaccinated in patients with chronic hepatitis B (CHB) has not been well characterized. The study aimed to explore the safety and specific antibody responses following COVID-19 vaccination among CHB patients.

Methods

Patients with CHB were included. All patients were vaccinated with two doses of inactivated vaccine (CoronaVac) or three doses of adjuvanted protein subunit vaccine (ZF2001). The adverse events were recorded and neutralizing antibody (NAb) were determined 14 days following the whole-course vaccination.

Results

A total of 200 patients with CHB were included. Specific NAb against SARS-CoV-2 were positive in 170 (84.6

SUBMITTER: Wu S 

PROVIDER: S-EPMC9944390 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature